Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab Plus (Chemo)Radiotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
NCT05784012Phase 2Active, not recruiting
- Start
- Nov 2023
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, dostarlimab in head and neck squamous cell carcinoma (HNSCC). Started Nov 2023; status: active, not recruiting.
02
Drugs
niraparibdostarlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05784012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784012.